Hexima Limited

Hexima (ASX:HXL) is a clinical stage, anti-infectives biotechnology company developing plant defensin peptides for applications as human therapeutics.

[Hexima Limited @HeximaLimited]

@WilsonsAdvisory has released an updated analysis on @HeximaLimited, with a view on the potential for success in phase II. Wilsons maintains its OVERWEIGHT rating and a $0.75 12-month price target. More: https://t.co/BewsBmoUoe
#asxresearch #pezadeftide #asxsmallcaps #asxhealth

[Hexima Limited @HeximaLimited]

Onychomycosis is more than a mild infection; it can also lead to other health issues. Hear Scientific Advisory Board member, Dr Robert Rosen explain how this infectious disease impacts quality of life.

https://t.co/muWbeV3aDK

#onychomycosis #pezadeftide #fungalinfection

[Hexima Limited @HeximaLimited]

In appreciation of all our phase I and phase II clinical trial participants to date, we say ‘Thank You’. Your involvement helps advance science and medicine and improve the lives of people around the world.

#CTD2022 #clinicaltrialsday #clinicalresearch #pezadeftide

[Hexima Limited @HeximaLimited]

Hexima CEO, Michael Aldridge, presented at the ShareCafe Hidden Gems Webinar on 29 April 2022. Mr Aldridge provided a company overview and discussed its phase II clinical trial.

The webinar recording and presentation are now available on our website: https://t.co/4nhbFnBiWf

[Hexima Limited @HeximaLimited]

@HeximaLimited is proud to release its “NailMail” quarterly activities and cashflow reports as part of the Company’s #Appendix4C for the quarter ended 31 March 2022. Full announcement: https://t.co/ljQ7eXE97z
#ASX $HXL

[Hexima Limited @HeximaLimited]

@HeximaLimited’s CEO Mr Michael Aldridge will be appearing today on @sharecafetweets Small/Micro Cap “Hidden Gems” Webinar at 12:30pm AEST.

Register here: https://t.co/bRAJ88kTit

#ASX $HXL #ShareCafe #webinar

[Sharecafe @sharecafetweets]

Friday's webinar will discuss internet software, biotechnology and cyber security @HeximaLimited $HXL, @ActivePortGroup $ATV & @CipherpointSW $CPT Register now https://t.co/UYbU8dRWBk

[Hexima Limited @HeximaLimited]

@HeximaLimited will be appearing on @sharecafetweets Micro/Small Cap “Hidden Gems” Webinar this Friday at 12:30pm AEST (April 29).

Register here: https://t.co/bRAJ88kTit

#ASX $HXL #ShareCafe #webinar

[Sharecafe @sharecafetweets]

Friday's webinar will discuss internet software, biotechnology and cyber security @HeximaLimited $HXL, @ActivePortGroup $ATV & @CipherpointSW $CPT Register now https://t.co/UYbU8dRWBk

[Hexima Limited @HeximaLimited]

Thank you to those that attended today's Investor Webinar and Q&A. @HeximaLimited CEO & COO discussed recent progress, upcoming milestones and presented #pezadeftide’s novel fungicidal mode of action. View the recording: https://t.co/SuVhSJn49Q

#ASX $HXL #AAD2022 #onychymycosis

[Hexima Limited @HeximaLimited]

Reminder that @HeximaLimited will be holding an investor webinar TODAY 9am AEDT. Register here: https://t.co/oqdFIFuG5g

#ASX $HXL #AAD2022 #onychymycosis #webinar

[Hexima Limited @HeximaLimited]

Reminder @HeximaLimited is holding a webinar at 9am AEST 5 April 2022 to give investors access to the information presented at @AADSkin (American Academy of Dermatology) annual meeting in Boston MA. Register: https://t.co/oqdFIFuG5g

#ASX $HXL #AAD2022 #onychomycosis #webinar

[Hexima Limited @HeximaLimited]

@HeximaLimited COO Nicole van der Weerden presented #pezadeftide’s novel fungicidal mode of action at @AADSkin (American Academy of Dermatology) on 25 March 2022 in Boston, MA.
More: https://t.co/6ytURafzpe

#ASX $HXL #AAD2022 #onychomycosis

[Hexima Limited @HeximaLimited]

This week @HeximaLimited launched its new website. The new look is more intuitive and user-friendly for investors and stakeholders. We invite you to experience the difference. https://t.co/g8c1FJMYaK

#ASX $HXL #newwebsite

[Hexima Limited @HeximaLimited]

@HeximaLimited will be holding a webinar at 9am AEST 5 April 2022 to give investors access to the information being presented at @AADSkin (American Academy of Dermatology) annual meeting in Boston, MA.
Register: https://t.co/oqdFIFuG5g

#ASX $HXL #AAD2022 #onychymycosis #webinar

[Hexima Limited @HeximaLimited]

Recently @WilsonsAdvisory published its initiation research report on @HeximaLimited with an OVERWEIGHT rating and a $0.75 12-month price target. View full report: https://t.co/5fqKa0C7sy

[Hexima Limited @HeximaLimited]

Hear from @HeximaLimited's COO Dr Nicole van der Weerden as part of a @CicadaInnov and @CSIRO course designed to assist in the commercialisation of innovative ways to tackle #antimicrobial resistance (#AMR). See more here: https://t.co/zZtLYw62HR

#ASX $HXL

[Hexima Limited @HeximaLimited]

@HeximaLimited is proud to release its “NailMail” quarterly activities and cashflow reports as part of the Company’s #Appendix4C for the quarter ended 31 December 2021. Full announcement: https://t.co/BE4wPIEay8
$HXL #ASX

[Hexima Limited @HeximaLimited]

BBC journalist, Vivienne Parry OBE, spoke with @HeximaLimited's CEO, Michael Aldridge, as part of @Edison_Inv_Res Open House: Global Healthcare 2022. View the recorded interview and research paper produced by Edison Group here: https://t.co/g8c1FJMYaK

$HXL #ASX #ausbiz

[Edison @Edison_Inv_Res]

@HeximaLimited CEO @AldridgeMichael delves deeper into the company's novel topical treatment for fungal nail infection. Find out why this ASX-listed company has caught our attention. $HXL #fungal #antifungal #treatment https://t.co/bVBV5JqsTv

[Hexima Limited @HeximaLimited]

Hear from @HeximaLimited's CEO Mr Michael Aldridge, appearing as part of @Edison_Inv_Res Open House: #Healthcare 2022, launching 25 Jan. To register for the event: https://t.co/tQm8mcYmWO $HXL #ASX #ausbiz

[Edison @Edison_Inv_Res]

@HeximaLimited is a pure-play #biotech focused on the progression of its sole clinical asset, pezadeftide, a novel topical treatment for fungal nail infection.

Read our QuickView ahead of Edison Open House: #Healthcare 2022, launching 25 Jan. $HXL
https://t.co/wVl3aq3rZL

[Hexima Limited @HeximaLimited]

While there are currently treatments on the market for #onychomycosis, they are not without their challenges. Hear @HeximaLimited's Scientific Advisory Board member, Dr Warren Joseph, explain the challenges currently faced by physicians. https://t.co/oB4iXi6kxy

#ASX $HXL

[Hexima Limited @HeximaLimited]

What is onychomycosis & what causes someone to develop it? @HeximaLimited's Scientific Advisory Board member, Dr Tracey Vlahovic provides some insights into the disease, & why more needs to be done to address this infection. https://t.co/NyJwcXvfAT $HXL #HXL #pezadeftide #ASX